Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
August 1, 2018
- Kyowa Kirin Sales Sag 2.8% but Net Profit Jumps on Capital Gains
August 1, 2018
- Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
August 1, 2018
- Takeda Integration Team Prepping for Shire Takeover: Weber
August 1, 2018
- AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
August 1, 2018
- Otsuka’s Guadecitabine Misses Primary Targets in Treatment-Naïve AML Patients in PIII
August 1, 2018
- Lonasen Patch Formulation Filed in Japan: Sumitomo Dainippon, Nitto Denko
August 1, 2018
- Eisai Grants Rights for Lorcaserin to Taiwan Biotech in China
August 1, 2018
- ASKA, Laboratoire HRA Strike Deal for IP Rights to Uterine Fibroid Treatment
August 1, 2018
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- Daiichi Sankyo Inks ADC License Pact with Glycotope
July 31, 2018
- Ono Seeks Add’l Indication for Onoact in Ventricular Arrhythmia
July 31, 2018
- Fujifilm to Shutter Gx, LLP Operations in March
July 30, 2018
- Mitsubishi Tanabe’s Erythropoietic Protoporphyria Earns FDA Fast-Track Status
July 30, 2018
- Chugai Forms Partnership with AI Upstart
July 30, 2018
- Chugai to Construct New Synthetic Research Building at Ukima Lab
July 30, 2018
- Chugai to Extend Operation Period of Singapore Research Subsidiary
July 30, 2018
- AI in Pharma - 1: Companies Going Digital in Sales Support but Still Embrace Rep Experience
July 30, 2018
- Chugai Filed Tecentriq for 1st Line Lung Cancer in March as Players Race to Grab Low PD-L1 Expressers
July 27, 2018
- Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…